{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:24:39Z","timestamp":1749813879043},"reference-count":0,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Endocrinol Diabetes"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\nIntroduction This study aimed to confirm the usefulness of basal insulin analogue plus oral antidiabetic drugs (OADs) for type 2 diabetes (T2D) patients inadequately controlled with premixed insulin with\/without OADs and assess the role of dipeptidyl peptidase-4 (DPP-4) inhibitors within this regimen in clinical practice.<\/jats:p><jats:p>\nMethods Spanish retrospective observational study that included 186 T2D patients with glycosylated hemoglobin (HbA1c) &gt;7% (53\u2009mmol\/mol) despite premixed insulin with\/without OADs who had been switched to basal insulin analogue plus OADs. Study data describing the situation before the treatment switch and 6 months later was retrospectively retrieved from patients\u2019 medical charts.<\/jats:p><jats:p>\nResults Switching to a basal insulin plus OADs decreased HbA1c (\u22121.0%, p&lt;0.001), fasting (\u221238.1\u2009mg\/dl, p&lt;0.001) and postprandial glycemia (\u221236.1\u2009mg\/dl, p&lt;0.001), with reduced body weight (\u22121.1\u2009kg, p&lt;0.001) and hypoglycemic episodes (\u221217.5%, p&lt;0.001). 68 (36.6%) patients received a basal insulin plus DPP-4 inhibitor\u00b1metformin and 74 (39.8%) plus metformin only. The DPP-4 inhibitor\u00b1metformin group showed a greater HbA1c reduction than the metformin group (1.3\u00b11.4% vs. 0.9\u00b11.0%, p=0.022), with no significant differences between groups in hypoglycemic episodes.<\/jats:p><jats:p>\nConclusions Basal insulin analogue plus OADs may be a useful treatment for type 2 diabetes patients inadequately controlled with premixed insulin. Administering DPP-4 inhibitors within this regimen may contribute to improve patients\u2019 glycemia, with a favorable weight-change profile and without increasing hypoglycemia risk.<\/jats:p>","DOI":"10.1055\/s-0043-113453","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T22:42:48Z","timestamp":1499985768000},"page":"268-276","source":"Crossref","is-referenced-by-count":4,"title":["Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors"],"prefix":"10.1055","volume":"126","author":[{"given":"Fernando","family":"G\u00f3mez-Peralta","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology and Nutrition, Hospital General de Segovia, Miguel Servet, S\/N, Segovia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Abreu","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology and Nutrition, Hospital General de Segovia, Miguel Servet, S\/N, Segovia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Mora-Navarro","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Centro de Salud Los Alpes, Calle Suecia, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"L\u00f3pez-Morandeira","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Centro de Salud Aquitania, Calle Aquitania, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"P\u00e9rez-Gutierrez","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Centro de Salud Mar\u00eda Jes\u00fas Hereza, Calle Jes\u00fas Miguel Haddad Blanco, Legan\u00e9s, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Cordero-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Centro de Salud Santa Mar\u00eda Benquerencia, Calle R\u00edo Alberche, S\/N, 45007 Toledo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Brito-Sanfiel","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology and Nutrition, Hospital Universitario Puerta de Hierro Majadahonda, Calle Manuel de Falla, Majadahonda, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2017,7,13]]},"container-title":["Experimental and Clinical Endocrinology &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-113453.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T22:40:39Z","timestamp":1527201639000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-113453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,13]]},"references-count":0,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2018,5,24]]},"published-print":{"date-parts":[[2018,5]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-113453","relation":{},"ISSN":["0947-7349","1439-3646"],"issn-type":[{"value":"0947-7349","type":"print"},{"value":"1439-3646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,13]]}}}